PGEN: Precigen, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 254.33
Enterprise Value ($M) 229.60
Book Value ($M) 55.38
Book Value / Share 0.19
Price / Book 4.59
NCAV ($M) 6.42
NCAV / Share 0.02
Price / NCAV 39.65

Profitability (mra)
Return on Invested Capital (ROIC) -2.28
Return on Assets (ROA) -0.73
Return on Equity (ROE) -0.95

Liquidity (mrq)
Quick Ratio 1.63
Current Ratio 1.63

Balance Sheet (mrq) ($M)
Current Assets 34.51
Assets 83.47
Liabilities 28.10
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
08-13 13D/A Kirk Randal J 40.50 25.22
02-27 13G/A Patient Capital Management, LLC 6.42 0.00
02-14 13G/A Ares Trading S.A. 8.30 0.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2024-03-19 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 634,272 1,717,023 36.94
2024-11-14 160,979 492,374 32.69
2024-11-13 158,792 513,229 30.94
2024-11-12 459,358 1,078,375 42.60
2024-11-11 415,156 1,103,053 37.64

(click for more detail)

Similar Companies
PCRX – Pacira BioSciences, Inc. PCVX – Vaxcyte, Inc.
PEPG – PepGen Inc. PHAT – Phathom Pharmaceuticals, Inc.
PHVS – Pharvaris N.V.


Financial data and stock pages provided by
Fintel.io